Johnson & Johnson seeds an ambitious open R&D program
Just how far can you go with an open R&D approach to drug development? Johnson & Johnson is stepping up with $3 million to seed a new program that intends to find out. J&J has set up a group called Healthy Minds, which will assist the International Mental Health Research Organization in setting up a collaborative effort on neuroscience drug programs. Faced with some Herculean R&D tasks, the campaign for a collaborative research approach to brain disorders will set out to marshal forces from Big Pharma, biotech, academia and government agencies on both sides of the Atlantic, testing the limits of the new “open innovation” movement in drug development.